A message from Diurnal – Chronocort Development Programme
A message from Diurnal:
CH EU-EU-0060 Date of preparation October 2019
Update for patient groups on Chronocort development programme and timetable
In response to questions we have received from patients, we would like to provide a short update about the plans and timelines for Chronocort marketing in Europe.
Chronocort has been designed to mimic the circadian rhythm of cortisol when given twice daily (last thing at night before sleep and first thing in the morning on waking).
After successful Phase I and II studies, Chronocort did not meet the primary endpoint in its European Phase III trial for the treatment of congenital adrenal hyperplasia (CAH). Diurnal performed further post-hoc analysis of the clinical trial data revealing important differences between Chronocort and the control arm. Formal Scientific Advice from the European Medicines Agency (EMA) confirmed the clinical and regulatory path for Chronocort as a treatment for adult and adolescent patients with CAH.
Thus, Diurnal intends to submit the Marketing Authorisation Application (MAA) in Q4 2019 based on the existing clinical trial data and would anticipate approval in early 2021.
Following a successful marketing authorisation application, Diurnal then intends to file an extension of the Chronocort marketing authorisation for adrenal insufficiency.
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
New NICE Guidelines – identification and management of adrenal insufficiency
The publication of new NICE (National Institute for Health and Care Excellence) guidelines - "Adrenal insufficiency: identification and management" marks a significant advancement in the management and treatment of primary, secondary and tertiary adrenal...
Survey: Paediatric Adrenal Insufficiency Education
This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...
Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It is an oral, selective ACTH antagonist. Atumelnant is now in Phase 2 of development and you can read the latest...